ConductScience.org, home

Trial · NCT02424539

Outcomes19

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYMean Change From Baseline in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over the First 2 Weeks Treatment PeriodBaseline and up to Week 2Intent-To-Treat (ITT) Population comprised of all randomized participants who received at least one dose of study treatment.Scores on a scaleLEAST_SQUARES_MEAN
SECONDARYNumber of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical ScaleWeek 2ITT PopulationParticipantsNUMBER
SECONDARYMean Change From Baseline of Intranasal Finding Score by Anterior Rhinoscopy at the First 2 WeeksBaseline and up to Week 2ITT PopulationScores on a scaleLEAST_SQUARES_MEAN
SECONDARYMean Change From Baseline Over the First 2 Weeks in the Daily, Reflective Total Ocular Symptoms Score (rTOSS)Baseline and up to Week 2ITT PopulationScores on a scaleLEAST_SQUARES_MEAN
SECONDARYMean Change From Baseline in Rescue Loratadine Use (Mean Rescue-free Days) Over the First 2 Weeks Treatment PeriodBaseline and up to Week 2ITT PopulationDaysLEAST_SQUARES_MEAN
SECONDARYMean Change From Baseline in Daily rTNSS Over the 4 Weeks Treatment PeriodBaseline and up to Week 4ITT PopulationScores on a scaleLEAST_SQUARES_MEAN
SECONDARYNumber of Participants Showing Response to the Therapy After 4 Weeks Treatment on a 7-point Categorical ScaleWeek 4ITT PopulationParticipantsNUMBER
SECONDARYMean Change From Baseline of Intranasal Finding Score by Anterior Rhinoscopy at the First 4 WeeksBaseline and up to Week 4ITT PopulationScores on a scaleLEAST_SQUARES_MEAN
SECONDARYMean Change From Baseline in the Daily rTOSS Over the 4 Weeks Treatment PeriodBaseline and up to Week 4ITT PopulationScores on a scaleLEAST_SQUARES_MEAN
SECONDARYMean Change From Baseline in Rescue Loratadine Use (Mean Rescue-free Days) Over the First 4 Weeks Treatment PeriodBaseline and up to Week 4ITT PopulationDaysLEAST_SQUARES_MEAN
SECONDARYNumber of Participants With Serious Adverse Events (SAEs) and Non-SAEs During the Treatment PeriodUp to Week 4ITT PopulationParticipantsNUMBER
SECONDARYNumber of Participants With Clinical Chemistry Values Outside the Normal RangeWeek 4ITT PopulationParticipantsNUMBER
SECONDARYNumber of Participants With Hematology Values Outside Normal RangeWeek 4ITT PopulationParticipantsNUMBER
SECONDARYNumber of Participants With Urinalysis Values Outside Normal RangeWeek 4ITT PopulationParticipantsNUMBER
SECONDARYNumber of Participants With Change From Baseline in Nasal ExaminationBaseline and Week 4ITT PopulationParticipantsNUMBER
SECONDARYChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)Baseline and Week 4ITT PopulationMillimeter of mercury (mmHg)MEAN
SECONDARYChange From Baseline in Heart RateBaseline and Week 4ITT PopulationBeats per minuteMEAN
SECONDARYChange From Baseline in TemperatureBaseline and Week 4ITT PopulationDegree CelsiusMEAN
SECONDARYChange From Baseline in Respiration RateBaseline and Week 4ITT PopulationBreaths per minuteMEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02424539/outcomes